In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kirin Pharma Co. Ltd.

Division of Kirin Holdings Co. Ltd.

Latest From Kirin Pharma Co. Ltd.

Dicerna and Kyowa Kirin form RNAi collaboration

The privately held US biotech company Dicerna Pharmaceuticals and Kyowa Hakko Kirin of Japan have entered into a collaboration and licence agreement for the R&D and commercialisation of RNAi drugs and delivery systems for oncology targets.

Cancer Japan

Antibodies emerge as key focus for Kyowa Kirin

Kyowa Hakko Kirin (KHK) is applying the technologies brought together by the merger of Kyowa Hakko and Kirin Pharma to an expanding pipeline of antibody products.

Cancer Orthopedics

One-off factors boost Kyowa Kirin's pharma ops

Pharmaceutical sales at Kyowa Hakko Kirin (KHK) in Japan jumped by 52% to ¥210.4 billion ($2.12 billion) in the year ended March 31st, boosted by one-off gains.

Cardiovascular Cancer

Modeling Human Breast Tumors in Mice

A major problem with xenograft tumor models is that they fail to capture the subsequent genetic changes that drive tumor development. Now, a research team from Aveo Pharmaceuticals has managed to insert a series of oncogenes into human breast tissue and grow that tissue in a mouse, creating in vivo models that mirror the staged development of human breast cancer.
BioPharmaceutical Platform Technologies
See All

Company Information